{"chunk_id": "medquad__chunk_12253", "source": "medquad", "text": "Institute suggests that individuals with metastatic clear cell renal cell carcinoma consider participation in a research study. IL-2 is offered as a treatment for this disease in some individuals because it has been shown to cause a complete disappearance of signs of this disease (remission) in 5% of treated patients.  As IL-2 may cause toxic side effects, it is most appropriate for patients who are in excellent health.  Sunitinib is offered because it has been shown to stabilize metastatic cle"}